PRD001 / PRD Therapeutics - LARVOL DELTA

Synergy of SOAT2-inhibitor PRD001 with resmetirom in reducing MASH and fibrosis in obese Ldlr-/-.Leiden mice (EASL 2026) - No abstract available

Preclinical • Fibrosis • Immunology • Metabolic Dysfunction-Associated Steatohepatitis • Obesity

A First-in-Human Study of PRD001 (clinicaltrials.gov) - P1 | N=86 | Recruiting | Sponsor: PRD Therapeutics, Inc.

New P1 trial

PRD Therapeutics Announces Initiation of First-in-Human Study for PRD001 (Businesswire) - "PRD Therapeutics...announced that the company recently initiated dosing in a First-in-Human (FIH) clinical trial of PRD001, a first-in-class SOAT2 (formerly known as ACAT2) selective inhibitor....'PRD001 has the potential to be the first-in-class effective and safe oral therapy for HoFH patients suffering from no or extremely low LDL receptor activity'....This FIH Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and the signs of early efficacy (LDL-C lowing effect, and liver fat quantitative value using MRI-PDFF) of PRD001 in adult healthy volunteers."

Trial status • Homozygous Familial Hypercholesterolemia